Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Arbutus Biopharma Corp (ABUS)

Arbutus Biopharma Corp (ABUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Arbutus Biopharma Reports 50% Functional Cure Rate in Phase 2a Clinical Trial for Chronic Hepatitis B Virus Quiver Quantitative, Inc. - Fri Nov 15, 8:16PM CST

Arbutus Biopharma reports 50% functional cure rate in HBeAg-negative patients with low HBsAg after IM-PROVE I trial.Quiver AI SummaryArbutus Biopharma Corporation announced promising results from its IM-PROVE...

ABUS : 3.46 (+0.58%)
Arbutus Biopharma and Barinthus Bio Report Encouraging Preliminary Results from Phase 2a IM-PROVE II Clinical Trial for Chronic Hepatitis B Virus Quiver Quantitative, Inc. - Fri Nov 15, 8:16PM CST

Imdusiran, VTP-300, and low-dose nivolumab demonstrated significant HBsAg reduction in a Phase 2a clinical trial for chronic hepatitis B.Quiver AI SummaryArbutus Biopharma and Barinthus Biotherapeutics...

ABUS : 3.46 (+0.58%)
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon GlobeNewswire - Fri Nov 15, 10:02AM CST

ABUS : 3.46 (+0.58%)
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B GlobeNewswire - Fri Nov 15, 10:01AM CST

ABUS : 3.46 (+0.58%)
Arbutus to Present at Jefferies London Healthcare Conference GlobeNewswire - Thu Nov 14, 6:30AM CST

ABUS : 3.46 (+0.58%)
Arbutus: Q3 Earnings Snapshot AP - Wed Nov 6, 6:40AM CST

Arbutus: Q3 Earnings Snapshot

ABUS : 3.46 (+0.58%)
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update GlobeNewswire - Wed Nov 6, 6:30AM CST

ABUS : 3.46 (+0.58%)
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update GlobeNewswire - Wed Oct 23, 6:30AM CDT

ABUS : 3.46 (+0.58%)
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024 GlobeNewswire - Tue Oct 15, 7:16AM CDT

ABUS : 3.46 (+0.58%)
Arbutus: Q2 Earnings Snapshot AP - Thu Aug 1, 6:41AM CDT

Arbutus: Q2 Earnings Snapshot

ABUS : 3.46 (+0.58%)

Barchart Exclusives

2 Energy Dividend Stocks Yielding 6% to Pick Now Barchart - 19 minutes ago
These two have been favorites among income-focused investors due to their high and consistent distribution yield. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot